Argenx to Acquire Forte Biosciences in $2.2bn Immunology Deal
The $77 per share offer marks an 86% premium as argenx expands its pipeline with Forte’s Phase II anti-CD122 antibody. Argenx will acquire Forte Biosciences for $2.2bn in equity value, pending regulatory and shareholder approval. The deal, set to close in Q3 2026, includes